Practitioner education. Patient details are anonymized and may be composites.
The Patient Who Felt Ready
A clinician we work with called on a Tuesday. His patient had a prior knee surgery and a recent meniscal procedure. Pain was a two out of ten. The patient wanted to squat heavy on Thursday.
Thursday came. He squatted. By Friday, the knee was significantly swollen.
The knee felt ready before it was ready. Load was advanced on how the knee felt that morning, and pain had improved faster than function had returned.
Pain is not readiness.
Why a Low Pain Score Can Mislead You
Pain and tissue capacity are different variables. A pain score describes how the knee feels right now. It does not describe how much load the tissue can tolerate.
This pattern is easy to miss because:
- Confidence often returns before strength, control, and tolerance do.
- Patients are tired of waiting and want normal activity before recovery is complete.
- Pain can decrease while swelling and impaired function remain.
Think about leaving the dentist while still numb. You feel fine. You still would not bite into a steak. The numbness says little about what the tissue can handle. A low pain score works the same way.
This is why criterion-based knee rehabilitation programs progress patients on objective signs such as joint effusion and strength, not time or pain alone [6].
Key takeaway: A low pain score is information. It is not clearance.
The Morning-After Response May Reveal More
The most useful signal arrived the next morning. Post-operative knee swelling after loading suggests the joint did not tolerate the session.
Criterion-based programs grade effusion and apply soreness rules. When soreness or swelling appears after a session, the next session is held or reduced, not advanced [6].
A practical morning-after check looks for:
- Increased swelling compared with before the session
- Reduced range of motion or new stiffness
- Altered gait, limping, or guarding
- Declining movement quality
- Symptoms that last longer than expected
- Reduced tolerance for the next rehabilitation session
The morning-after response is one data point, not a standalone decision rule. It belongs inside a broader assessment of the surgical plan, rehabilitation milestones, and overall status. After meniscal repair, progression also depends on tear type, repair technique, and objective return-to-activity criteria [7].
A Simple Framework for Load Progression
This is an educational reasoning framework, not a universal protocol, and it does not replace surgeon clearance or an individualized plan.
- Review the patient's rehabilitation milestones. Where is the patient relative to the plan for this procedure?
- Assess strength, control, range of motion, and movement quality. Look at the whole picture, not a number on a pain scale.
- Observe the response during the session. Watch for guarding, compensation, or loss of form as load rises.
- Reassess swelling and function the following morning. Decide the next step after the check, not before it.
- Progress gradually when the response remains acceptable. Change one variable at a time.
- Communicate with the treating surgeon whenever post-operative clearance is required.
Progress load based on function and response, not pain score alone.
Where Peptide Research Fits Into the Conversation
The following compounds are discussed in practitioner education and research contexts. They are not substitutes for rehabilitation, surgical clearance, or clinical judgment.
BPC-157
BPC-157 is commonly discussed in tendon, ligament, and tissue-repair research. A 2025 literature review notes that most studies are limited to small animal models and that human studies are scarce [8]. FDA's July 2026 briefing document likewise found a lack of evidence to support effectiveness for the use it evaluated [3]. BPC-157 is not proven, approved, or standard of care.
Thymosin Beta-4
Thymosin beta-4 is discussed in soft-tissue and wound-healing research. Reviews describe mechanisms such as actin binding, cell migration, and reduced scar formation, largely from laboratory and animal models [9]. Mechanistic findings are not proven patient outcomes.
GHK-Cu
GHK-Cu is discussed in relation to collagen, extracellular matrix, and tissue remodeling. A 2018 review reports increased collagen, elastin, and glycosaminoglycan synthesis in cell and animal studies, with most human data coming from topical cosmetic use [10]. Evidence depends on formulation, route, indication, and study model, so findings from one setting do not transfer to another.
Regulatory Note
Regulatory status changes. Practitioners should verify current FDA guidance, applicable state rules, pharmacy status, and professional requirements before making clinical or sourcing decisions.
As of October 15, 2026, FDA's primary sources show that BPC-157 and TB-500 are no longer on FDA's Category 2 list because their nominations were withdrawn [2]. That is not a safety clearance, and neither sits in Category 1 [1]. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 for ulcerative colitis, the use FDA evaluated [4]. FDA's briefing document concluded the criteria weigh against adding it to the 503A Bulks List [3]. News reports say the committee voted 8 to 6, with one abstention, to recommend it anyway [5]. That vote is advice, not approval. FDA has not issued a final determination or posted official results [3][4]. None of these compounds is a component of an FDA-approved drug [3], and non-injectable GHK-Cu remains in Category 1, under evaluation [1].
Compound discussion does not replace rehabilitation, surgical clearance, load management, monitoring, or clinical judgment.
When This Framework Should Not Be Used as a Shortcut
This reasoning model is not for:
- Patients trying to replace rehabilitation with a peptide
- Patients progressing after surgery without appropriate surgeon clearance
- Clinicians using a pain score as the only decision variable
- Anyone treating educational information as a prescription or individualized medical advice
- Anyone promising patient outcomes
The Practical Takeaway
Advance loading from rehabilitation milestones, movement quality, session response, and the morning-after check. Never rely on pain score alone.
Pain can be useful information. It is not proof of readiness.
Frequently Asked Questions
Can pain improve before a knee is ready for heavy loading?
Yes. Pain often improves before tissue capacity, strength, and tolerance to load have fully returned. A pain score reflects how the knee feels in the moment, not how much stress it can absorb. Criterion-based rehabilitation programs use objective measures such as effusion and strength, not pain alone, to decide when a patient is ready to progress [6].
Why can knee swelling appear the day after exercise?
The joint's response to load is often delayed. A patient may feel fine during a session, then wake up with new effusion, stiffness, or reduced motion. Rehabilitation programs treat next-day swelling or soreness as a sign the previous session exceeded tolerance, and they reduce or hold the next session rather than advance [6].
What should clinicians evaluate besides pain?
Look at swelling, range of motion, strength, movement quality, gait, and how the patient tolerated the previous session. Compare these against the rehabilitation milestones for the specific procedure. After meniscal repair, tear type and repair technique also shape what safe progression looks like [7]. Pain remains one input, but it should never be the only one.
Is a low pain score enough to progress rehabilitation?
No. A low pain score is information, not clearance. Patients often feel confident and pain-free while swelling, strength deficits, or impaired control remain. Decisions about load should combine rehabilitation milestones, function, the response during the session, and the morning-after check, with surgeon clearance where it is required [6][7].
What is BPC-157 being studied for?
BPC-157 is most often discussed in tendon, ligament, gut, and tissue-repair research. A 2025 review found that most studies are in small animal models and that human studies are scarce [8]. FDA's 2026 evaluation found a lack of evidence to support effectiveness for the use it reviewed [3]. BPC-157 musculoskeletal research remains preclinical, and it is not an approved treatment.
What is Thymosin Beta-4 being studied for?
Thymosin beta-4 is discussed in soft-tissue and wound-healing research. Published reviews describe actin binding, cell migration, and reduced scar formation, mostly in laboratory and animal models [9]. These are mechanistic findings. They are not the same as proven patient outcomes, and they should not be presented as evidence that the compound works clinically for musculoskeletal recovery.
What is GHK-Cu being studied for?
GHK-Cu is discussed in collagen, extracellular matrix, and tissue-remodeling research. A 2018 review describes increased collagen, elastin, and glycosaminoglycan synthesis in cell and animal studies, with most human data from topical cosmetic products [10]. Results vary by formulation, route, indication, and study model, so evidence from skin studies should not be extended to joints or tendons.
Are these compounds FDA-approved treatments for knee recovery?
No. None of BPC-157, Thymosin Beta-4, or GHK-Cu is a component of an FDA-approved drug [3]. In April 2026, BPC-157 and TB-500 came off FDA's Category 2 list because their nominations were withdrawn, not because FDA cleared them [2]. In July 2026, an FDA advisory committee voted to recommend BPC-157 for the 503A Bulks List [5]. That vote is advice, not approval, and FDA has not finalized a decision [3][4].
Can peptides replace physical therapy after surgery?
No. Rehabilitation, surgical clearance, load management, and monitoring are the foundation of post-operative knee recovery [6][7]. The compounds discussed here have limited human evidence and no FDA approval for musculoskeletal recovery [3][8]. A patient who wants a peptide instead of rehabilitation is asking for a shortcut that the evidence does not support.
What should clinicians verify before discussing these compounds?
Verify the current FDA status of each compound, including its 503A category and any advisory committee or rulemaking activity [1][4]. Confirm applicable state rules, pharmacy status, and professional requirements. Confirm surgical clearance for post-operative patients. Then present the evidence honestly: largely preclinical, limited in humans, and subject to change.
References
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (503A category list). Updated May 14, 2026. fda.gov/media/94155/download
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026. fda.gov
- U.S. Food and Drug Administration. FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. fda.gov/media/193343/download
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (meeting page and event materials). fda.gov
- ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026. abcnews.com
- Adams D, Logerstedt DS, Hunter-Giordano A, Axe MJ, Snyder-Mackler L. Current concepts for anterior cruciate ligament reconstruction: a criterion-based rehabilitation progression. J Orthop Sports Phys Ther. 2012;42(7):601–614. doi:10.2519/jospt.2012.3871. PMID 22402434
- Sherman SL, DiPaolo ZJ, Ray TE, Sachs BM, Oladeji LO. Meniscus Injuries: A Review of Rehabilitation and Return to Play. Clin Sports Med. 2020;39(1):165–183. doi:10.1016/j.csm.2019.08.004. PMID 31767104
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID 40005999
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. doi:10.1517/14712598.2012.634793. PMID 22074294
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520